Karolinska Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
September 2018
126
About the Report
About the Report
Summary
Karolinska Institutet (KI) is a medical university that offers education services. The university provides education and research in the fields of medicine and health sciences. Its education courses include audiology, biomedicine, biomedical lab science, dental hygiene, medicine, nursing, occupational therapy and others. KI offers optometry, physiotherapy, psychology, public health science, speech and language pathology, and radiography. KI provides supplementary training on midwifery, and psychotherapy. It offers healthcare, education, research and development. The university's research areas include cancer and hematology, cell, molecular and structural biology, endocrinology and metabolism, epidemiology and public health sciences, and health care sciences. KI is headquartered in Stockholm, Sweden.
Karolinska Institute-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Karolinska Institute, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Karolinska Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Karolinska Institute, Medical Devices Deals, 2012 to YTD 2018 11
Karolinska Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Karolinska Institute, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
RXi Pharma and Karolinska Institutet Enter into Research Partnership 14
LIDDS Enters into Research Agreement with Karolinska Institute 15
Takeda Pharma, Karolinska Institutet and Structural Genomics Consortium Enter into Agreement 16
NeuroVive Pharma Enters into Agreement with Karolinska Institutet 17
Karolinska Institutet Partners with Johnson & Johnson Companies 18
Canqura Oncology Enters into Agreement with Karolinska Institutet 19
Lion Biotechnologies Enters into Clinical Trial Agreement with Karolinska University Hospital 20
Sprint Bioscience Enters into Research Agreement with Karolinska Institutet 21
Scancell Extends Research Agreement with Karolinska Institutet 22
Biovica Enters into Research Agreement with Karolinska Institutet 23
Ferring Pharma Enters into Co-Development Agreement with Karolinska Institutet 24
Sorrento Therapeutics Enters into Partnership with Karolinska Institutet 25
Thermo Fisher Scientific Enters into Agreement with Karolinska Institute 26
Idogen Partners with Karolinska Institutet 27
Moderna Therapeutics Enters into Discovery Agreement with Karolinska Institutet and Karolinska University Hospital 28
Karolinska University Hospital Enters Into Research Agreement With GE Healthcare For Cell Therapy 29
Licensing Agreements 30
Oblique Therapeutics Enters Licensing Agreement with National Institutes of Health and Karolinska Institutet 30
Karolinska Institute-Key Competitors 31
Karolinska Institute-Key Employees 32
Karolinska Institute-Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Corporate Communications 34
Apr 07, 2017: Government re-appoints four members of the KI board 34
Government and Public Interest 35
Sep 14, 2018: NIH grant of 526,000 USD to Craig Wheelock 35
Aug 31, 2018: Similar changes in the brains of patients with ADHD and emotional instability 36
Aug 26, 2018: Oxygen therapy for patients suffering from a heart attack does not prevent heart failure 37
Aug 23, 2018: Treatment for severe heartburn prevents cancer 38
Aug 23, 2018: Dramatic development of immune system after birth 39
Aug 15, 2018: Prestigious grant for research on ALS 41
Aug 08, 2018: New method reveals cell development 42
Aug 06, 2018: Red blood cells cause cardiovascular injury in type 2 diabetes 43
Jul 25, 2018: New potential target for treatment of diabetes 44
Jul 24, 2018: Karolinska Institute: New potential target for treatment of diabetes 45
Jul 17, 2018: Sleep disorders can be associated with increased risk of dementia 46
Jul 04, 2018: Solvents and smoking are associated with increased risk of MS 47
Jun 28, 2018: Newly detected stop signal in cell division prevents cancer 48
Jun 25, 2018: LIDDS' NanoZolid technology recognized through publication of scientific article in Journal of Drug Delivery Science and Technology 49
Jun 19, 2018: Mechanism controlling multiple sclerosis risk identified 50
May 31, 2018: Inefficient fat degradation can be behind obesity 51
May 31, 2018: Fat degradation helps the tumor grow in case of acid deficiency 52
May 28, 2018: Anti-inflammatory treatment stops aggressive childhood cancer 53
May 25, 2018: Karolinska Institutet: Aggression neurons identified 54
May 21, 2018: Cell types underlying schizophrenia identified 55
May 18, 2018: New strategy for curing chronic hepatitis B infection 56
May 17, 2018: New strategy to cure chronic hepatitis B infection 57
Apr 24, 2018: Imagined and real movements are controlled by the brain in the same way 58
Apr 19, 2018: KI researchers awarded grants from the Swedish Childhood Cancer Foundation 59
Apr 17, 2018: New disease model to facilitate development of ALS and MS drugs 60
Apr 05, 2018: PCSK9 inhibitors have unexpected anti-inflammatory effects 61
Mar 13, 2018: New biomarkers for childhood cancer neuroblastoma 62
Mar 08, 2018: Fluoroquinolones linked to increased risk of acute aortic disease 63
Mar 06, 2018: Karolinska Institute: The body's glucostat identified 64
Mar 01, 2018: Promising therapeutic approach for spinal cord injuries 65
Mar 01, 2018: New promising approach to healing spinal cord injuries 66
Feb 28, 2018: Lithium treatment for bipolar disorder linked to lowest risk of rehospitalisation 67
Feb 23, 2018: Stem cell study may result in stronger muscles in old age 68
Feb 14, 2018: Karolinska Institutet: Atlas of brain blood vessels provides fresh clues to brain diseases 69
Feb 13, 2018: New method maps the dopamine system in parkinson patients 70
Feb 06, 2018: Asthma medicine possible treatment for pulmonary edema 71
Jan 23, 2018: Reduced dental anxiety among children with internet-based CBT 72
Jan 19, 2018: Factor that doubles the risk of death from breast cancer identified 73
Jan 18, 2018: New method to stop cells dividing could help fight cancer 74
Jan 17, 2018: New way to stop the growth of breast cancer cells 75
Jan 16, 2018: Oxysterols guide gut immune cells and are involved in inflammatory bowel disease 76
Jan 12, 2018: Karolinska Institutet: Genetic analysis can improve depression therapy 77
Jan 12, 2018: Gene analysis can provide better treatment for depression 78
Jan 09, 2018: Large-scale protein analysis can provide new possibilities for diagnosis and treatment in dementia 79
Dec 22, 2017: Salamander genome gives clues about unique regenerative ability 80
Dec 05, 2017: Karolinska Institute: Polyunsaturated fatty acids linked to reduced allergy risk 81
Dec 04, 2017: Karolinska Institute: New approach to predict respiratory allergy in early childhood 82
Nov 20, 2017: Enterovirus vaccine prevents virus-induced diabetes in a Type 1 diabetes experimental model 83
Oct 25, 2017: Thrombotic drugs are associated with decreased dementia risk in atrial fibrillation 84
Oct 24, 2017: Blood-thinning drugs appear to protect against dementia as well as stroke in AF patients 85
Oct 09, 2017: Karolinska Institutet: Safe to treat dementia patients with clot-busting drugs 87
Oct 04, 2017: Asthma increases the risk of complications during pregnancy and childbirth 88
Sep 21, 2017: Inflammatory bowel disease in childhood associated with increased risk of cancer 89
Sep 12, 2017: Relapse rare in young men after antireflux surgery 90
Aug 30, 2017: Thorough analysis reveals immune system dynamics after immunotherapy 91
Aug 28, 2017: Anti-inflammatory drugs can inhibit muscle growth 92
Aug 18, 2017: Oral contraceptives linked to reduced risk of rheumatoid arthritis 93
Aug 09, 2017: Method developed that gives researchers better conditions for studying insulin-producing cells 94
Jul 18, 2017: Fewer infections in mechanical heart valves 95
Jul 11, 2017: New tool demonstrates differences in human immune systems 96
Jun 22, 2017: Presence of protein important clue to tumour regression in neuroblastoma 97
Jun 22, 2017: The presence of the protein KIF1B? can play a central role for the outcome of a neuroblastoma diagnosis 98
Jun 09, 2017: Lithium medication protects against suicide 99
Jun 07, 2017: Fewer relapses in schizophrenia with long-acting injections 100
Jun 06, 2017: New possible target for cancer treatment 101
May 24, 2017: Making biological drugs with spider silk protein 102
May 22, 2017: New findings on formation and malformation of blood vessels 103
May 17, 2017: New way of preventing pneumococcal brain invasion 104
May 16, 2017: Spread of tau protein measured in the brains of Alzheimer's patients 105
May 15, 2017: Corticosteroid treatment increases survival of preterm infants within hours 106
May 08, 2017: Newly discovered malaria mechanism gives hope to pregnant women 107
Mar 14, 2017: Major research project provides new clues to schizophrenia 108
Feb 20, 2017: Hope for new treatment for Huntington's disease 109
Feb 07, 2017: NattoPharma Named Partner For Horizon 2020 EU Research Grant 110
Product News 111
Jul 11, 2017: New potential treatment for aggressive types of childhood cancer 111
Mar 12, 2018: Aggressive breast cancer can be transformed into a treatable form 112
Feb 15, 2018: Science Translational Medicine publishes research results from Oblique Therapeutics and Karolinska Institute on a new treatment of advanced cancer 113
Feb 02, 2018: Successful NK cell-based immunotherapy for leukaemia 114
Jan 12, 2017: Inhibition of EZH2 might be new therapy of multiple myeloma 115
Other Significant Developments 116
Sep 04, 2018: New project to improve drugs safety in East Africa 116
Aug 27, 2018: Microvascular dysfunction: a common cause of heart failure with preserved pumping capacity 117
Aug 09, 2018: Karolinska Institute: Detailed atlas of the nervous system 118
Jul 30, 2018: LCSB researchers predict cell conversion factors 119
Jul 06, 2018: Re search ers de ve lop a new method for turn ing skin cells into pluri po tent stem cells 120
Jun 26, 2018: AI could improve prostate cancer diagnosis and treatment 121
Jun 11, 2018: Immune system does not recover despite cured hepatitis C infection 123
Jun 11, 2018: Genome-editing tool could increase cancer risk 124
Jun 26, 2017: KCC improves patient safety of advanced therapy drugs 125
Appendix 126
Methodology 126
About GlobalData 126
Contact Us 126
Disclaimer 126
List of Figure
List of Figures
Karolinska Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Karolinska Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Karolinska Institute, Medical Devices Deals, 2012 to YTD 2018 11
List of Table
List of Tables
Karolinska Institute, Pharmaceuticals & Healthcare, Key Facts 2
Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Karolinska Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Karolinska Institute, Deals By Therapy Area, 2012 to YTD 2018 10
Karolinska Institute, Medical Devices Deals, 2012 to YTD 2018 11
Karolinska Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
RXi Pharma and Karolinska Institutet Enter into Research Partnership 14
LIDDS Enters into Research Agreement with Karolinska Institute 15
Takeda Pharma, Karolinska Institutet and Structural Genomics Consortium Enter into Agreement 16
NeuroVive Pharma Enters into Agreement with Karolinska Institutet 17
Karolinska Institutet Partners with Johnson & Johnson Companies 18
Canqura Oncology Enters into Agreement with Karolinska Institutet 19
Lion Biotechnologies Enters into Clinical Trial Agreement with Karolinska University Hospital 20
Sprint Bioscience Enters into Research Agreement with Karolinska Institutet 21
Scancell Extends Research Agreement with Karolinska Institutet 22
Biovica Enters into Research Agreement with Karolinska Institutet 23
Ferring Pharma Enters into Co-Development Agreement with Karolinska Institutet 24
Sorrento Therapeutics Enters into Partnership with Karolinska Institutet 25
Thermo Fisher Scientific Enters into Agreement with Karolinska Institute 26
Idogen Partners with Karolinska Institutet 27
Moderna Therapeutics Enters into Discovery Agreement with Karolinska Institutet and Karolinska University Hospital 28
Karolinska University Hospital Enters Into Research Agreement With GE Healthcare For Cell Therapy 29
Oblique Therapeutics Enters Licensing Agreement with National Institutes of Health and Karolinska Institutet 30
Karolinska Institute, Key Competitors 31
Karolinska Institute, Key Employees 32
Karolinska Institute, Other Locations 33
Karolinska Institute, Subsidiaries 33
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.